68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors
- PMID: 22072704
- DOI: 10.2967/jnumed.111.091165
68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors
Abstract
Radiolabeled somatostatin analogs represent valuable tools for both in vivo diagnosis and therapy of neuroendocrine tumors (NETs) because of the frequent tumoral overexpression of somatostatin receptors (sst). The 2 compounds most often used in functional imaging with PET are (68)Ga-DOTATATE and (68)Ga-DOTATOC. Both ligands share a quite similar sst binding profile. However, the in vitro affinity of (68)Ga-DOTATATE in binding the sst subtype 2 (sst2) is approximately 10-fold higher than that of (68)Ga-DOTATOC. This difference may affect their efficiency in the detection of NET lesions because it is the sst2 that is predominantly overexpressed in NET. We thus compared the diagnostic value of PET/CT with both radiolabeled somatostatin analogs ((68)Ga-DOTATATE and (68)Ga-DOTATOC) in the same NET patients.
Methods: Forty patients with metastatic NETs underwent (68)Ga-DOTATOC and (68)Ga-DOTATATE PET/CT as part of the work-up before prospective peptide receptor radionuclide therapy. The performance of both imaging methods was analyzed and compared for the detection of individual lesions per patient and for 8 defined body regions. A region was regarded positive if at least 1 lesion was detected in that region. In addition, radiopeptide uptake in terms of the maximal standardized uptake value (SUVmax) was compared for concordant lesions and renal parenchyma.
Results: Seventy-eight regions were found positive with (68)Ga-DOTATATE versus 79 regions with (68)Ga-DOTATOC (not significant). Overall, however, significantly fewer lesions were detected with (68)Ga-DOTATATE than with (68)Ga-DOTATOC (254 vs. 262, P < 0.05). Mean (68)Ga-DOTATATE SUVmax across all lesions was significantly lower than (68)Ga-DOTATOC (16.0 ± 10.8 vs. 20.4 ± 14.7, P < 0.01). Mean SUVmax for renal parenchyma was not significantly different between (68)Ga-DOTATATE and (68)Ga-DOTATOC (12.7 ± 3.0 vs. 13.2 ± 3.3).
Conclusion: (68)Ga-DOTATOC and (68)Ga-DOTATATE possess a comparable diagnostic accuracy for the detection of NET lesions, with (68)Ga-DOTATOC having a potential advantage. The approximately 10-fold higher affinity for the sst2 of (68)Ga-DOTATATE does not prove to be clinically relevant. Quite unexpectedly, SUVmax of (68)Ga-DOTATOC scans tended to be higher than their (68)Ga-DOTATATE counterparts.
Similar articles
-
Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.Recent Results Cancer Res. 2013;194:353-71. doi: 10.1007/978-3-642-27994-2_18. Recent Results Cancer Res. 2013. PMID: 22918768
-
Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.J Nucl Med. 2014 Feb;55(2):204-10. doi: 10.2967/jnumed.113.126177. Epub 2013 Dec 30. J Nucl Med. 2014. PMID: 24379222 Clinical Trial.
-
Head-to-Head Comparison of 64Cu-DOTATATE and 68Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors.J Nucl Med. 2017 Mar;58(3):451-457. doi: 10.2967/jnumed.116.180430. Epub 2016 Sep 22. J Nucl Med. 2017. PMID: 27660147 Clinical Trial.
-
Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors.Scand J Gastroenterol. 2015 Jun;50(6):740-7. doi: 10.3109/00365521.2015.1033454. Scand J Gastroenterol. 2015. PMID: 25959100 Free PMC article. Review.
-
PET tracers for somatostatin receptor imaging of neuroendocrine tumors: current status and review of the literature.Future Oncol. 2014 Nov;10(14):2259-77. doi: 10.2217/fon.14.139. Future Oncol. 2014. PMID: 25471038 Review.
Cited by
-
Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis.Endocrine. 2012 Aug;42(1):80-7. doi: 10.1007/s12020-012-9631-1. Epub 2012 Feb 20. Endocrine. 2012. PMID: 22350660 Review.
-
Survival According to Therapy Regimen for Small Intestinal Neuroendocrine Tumors.J Clin Med. 2022 Apr 22;11(9):2358. doi: 10.3390/jcm11092358. J Clin Med. 2022. PMID: 35566487 Free PMC article.
-
Free somatostatin receptor fraction predicts the antiproliferative effect of octreotide in a neuroendocrine tumor model: implications for dose optimization.Cancer Res. 2013 Dec 1;73(23):6865-73. doi: 10.1158/0008-5472.CAN-13-1199. Epub 2013 Sep 30. Cancer Res. 2013. PMID: 24080280 Free PMC article.
-
The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society.Pancreas. 2017 Jul;46(6):715-731. doi: 10.1097/MPA.0000000000000846. Pancreas. 2017. PMID: 28609357 Free PMC article. Review.
-
Phage Display Selection, In Vitro Characterization, and Correlative PET Imaging of a Novel HER3 Peptide.Mol Imaging Biol. 2018 Apr;20(2):300-308. doi: 10.1007/s11307-017-1106-6. Mol Imaging Biol. 2018. PMID: 28733706 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical